Quarterly ResultAug 6, 2026, 09:26 AM
Iovance Q2 Revenue Jumps 66% to $99.3M; Net Loss Narrows
AI Summary
Iovance Biotherapeutics reported a significant increase in product revenue for Q2 2026, reaching $99.3 million, a 66% rise year-over-year. The company also substantially narrowed its net loss to $47.3 million, or $0.11 per share, compared to $111.7 million, or $0.33 per share, in the prior year. Regulatory progress for Amtagvi® continues with marketing authorization in Australia and resubmission in the UK, alongside ongoing clinical trials for pipeline candidates. The company believes it has sufficient capital to fund operations for at least the next twelve months.
Key Highlights
- Product revenue for Q2 2026 increased 66% year-over-year to $99.3 million.
- Net loss for Q2 2026 narrowed to $47.3 million from $111.7 million year-over-year.
- Diluted net loss per share improved to $(0.11) in Q2 2026 from $(0.33) year-over-year.
- Year-to-date product revenue grew 56% to $170.7 million.
- Net cash used in operating activities improved to $132.9 million YTD 2026 from $171.1 million YTD 2025.
- Cash, cash equivalents, and short-term investments totaled $297.7 million as of June 30, 2026.
- Amtagvi® received marketing authorization with conditions in Australia on June 4, 2026.
- UK marketing authorization application for Amtagvi® was resubmitted in July 2026.
Price Impact
More from IOVA